JP2020511494A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511494A5 JP2020511494A5 JP2019551608A JP2019551608A JP2020511494A5 JP 2020511494 A5 JP2020511494 A5 JP 2020511494A5 JP 2019551608 A JP2019551608 A JP 2019551608A JP 2019551608 A JP2019551608 A JP 2019551608A JP 2020511494 A5 JP2020511494 A5 JP 2020511494A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- composition
- natriuretic peptide
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022070710A JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475147P | 2017-03-22 | 2017-03-22 | |
| US62/475,147 | 2017-03-22 | ||
| PCT/US2018/023491 WO2018175534A1 (en) | 2017-03-22 | 2018-03-21 | Npra agonists, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022070710A Division JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511494A JP2020511494A (ja) | 2020-04-16 |
| JP2020511494A5 true JP2020511494A5 (https=) | 2021-04-01 |
| JP7126270B2 JP7126270B2 (ja) | 2022-08-26 |
Family
ID=63585777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551608A Active JP7126270B2 (ja) | 2017-03-22 | 2018-03-21 | Ｎｐｒａアゴニスト、組成物およびその使用 |
| JP2022070710A Withdrawn JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022070710A Withdrawn JP2022090049A (ja) | 2017-03-22 | 2022-04-22 | Ｎｐｒａアゴニスト、組成物およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200017567A1 (https=) |
| EP (1) | EP3601314A4 (https=) |
| JP (2) | JP7126270B2 (https=) |
| KR (1) | KR102714599B1 (https=) |
| CN (1) | CN110603260B (https=) |
| AU (2) | AU2018239352A1 (https=) |
| BR (1) | BR112019019720A2 (https=) |
| CA (1) | CA3056433A1 (https=) |
| EA (1) | EA201992226A1 (https=) |
| IL (1) | IL269388B2 (https=) |
| MX (1) | MX2019010960A (https=) |
| MY (1) | MY201165A (https=) |
| PH (1) | PH12019550163A1 (https=) |
| SG (1) | SG11201908580XA (https=) |
| WO (1) | WO2018175534A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020236688A1 (en) | 2019-05-22 | 2020-11-26 | Merck Sharp & Dohme Corp. | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| EP3972589B1 (en) * | 2019-05-22 | 2024-07-03 | Merck Sharp & Dohme LLC | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes |
| US20230241164A1 (en) * | 2020-06-12 | 2023-08-03 | Hirofumi Tachibana | C-Type Natriuretic Peptides and Methods Thereof in Treating Cancer |
| IL298980A (en) * | 2020-06-12 | 2023-02-01 | Pharmain Corp | C-type natriuretic peptides and methods thereof in treating acute lung injury |
| IL320341A (en) * | 2022-10-21 | 2025-06-01 | Lilly Co Eli | Long-acting natriuretic peptides and uses thereof |
| EP4612167A1 (en) * | 2022-11-02 | 2025-09-10 | Novo Nordisk A/S | Cnp compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985722A (en) * | 1973-12-12 | 1976-10-12 | Ajinomoto Co., Inc. | Process for preparing N-higher aliphatic acyl derivatives of amino acids, peptides or proteins |
| FR2687156B1 (fr) * | 1992-02-12 | 1994-04-01 | Roussel Uclaf | Nouveaux derives peptidiques, procede de preparation et application a titre de medicaments de ces nouveaux derives. |
| CN1062311C (zh) * | 1996-12-27 | 2001-02-21 | 中国医学科学院基础医学研究所 | 人白细胞介素2衍生物与人心钠素衍生物的融合基因、其蛋白产物及应用 |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| AU2003297583B2 (en) * | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
| EP2162464A1 (en) * | 2007-06-06 | 2010-03-17 | Boehringer Ingelheim International GmbH | Natriuretic fusion proteins |
| US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| US8933197B2 (en) * | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| CN101809029B (zh) * | 2008-05-23 | 2016-06-15 | 第一三共株式会社 | 具有延长目标肽的血浆半衰期作用的肽 |
| ES2608457T3 (es) * | 2009-05-20 | 2017-04-11 | Biomarin Pharmaceutical Inc. | Variantes de péptido natriurético de tipo C |
| JP6055779B2 (ja) * | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| CN103402534B (zh) * | 2011-02-23 | 2016-10-12 | 麦德林制药私人有限公司 | 用于治疗充血性心力衰竭的治疗方法 |
| EP2678028A2 (en) * | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
-
2018
- 2018-03-21 EA EA201992226A patent/EA201992226A1/ru unknown
- 2018-03-21 BR BR112019019720A patent/BR112019019720A2/pt unknown
- 2018-03-21 EP EP18771099.1A patent/EP3601314A4/en active Pending
- 2018-03-21 CA CA3056433A patent/CA3056433A1/en active Pending
- 2018-03-21 SG SG11201908580X patent/SG11201908580XA/en unknown
- 2018-03-21 IL IL269388A patent/IL269388B2/en unknown
- 2018-03-21 AU AU2018239352A patent/AU2018239352A1/en not_active Abandoned
- 2018-03-21 MY MYPI2019005393A patent/MY201165A/en unknown
- 2018-03-21 CN CN201880028963.9A patent/CN110603260B/zh active Active
- 2018-03-21 JP JP2019551608A patent/JP7126270B2/ja active Active
- 2018-03-21 MX MX2019010960A patent/MX2019010960A/es unknown
- 2018-03-21 KR KR1020197031122A patent/KR102714599B1/ko active Active
- 2018-03-21 WO PCT/US2018/023491 patent/WO2018175534A1/en not_active Ceased
-
2019
- 2019-09-12 PH PH12019550163A patent/PH12019550163A1/en unknown
- 2019-09-20 US US16/577,947 patent/US20200017567A1/en active Pending
-
2022
- 2022-04-22 JP JP2022070710A patent/JP2022090049A/ja not_active Withdrawn
-
2025
- 2025-02-21 AU AU2025201270A patent/AU2025201270A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511494A5 (https=) | ||
| US8603969B2 (en) | Pancreatic polypeptide family motifs and polypeptides comprising the same | |
| JP4173914B2 (ja) | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 | |
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| JP2017518303A5 (https=) | ||
| JP2014521684A5 (https=) | ||
| MX2014012625A (es) | Variantes de oxintomodulina de accion prolongada y metodos para su produccion. | |
| JP7126270B2 (ja) | Ｎｐｒａアゴニスト、組成物およびその使用 | |
| JP5687266B2 (ja) | 大動脈線維症の治療のための組成物および方法 | |
| US10172914B2 (en) | Combination | |
| WO2016144968A1 (en) | Relaxin therapy for disorders of the diaphragm | |
| JPWO2021094259A5 (https=) | ||
| HK40088755A (zh) | Hbv和hdv感染的联合治疗 | |
| Javaheri et al. | Apolipoprotein M improves survival in congestive heart failure via enhanced Akt signaling | |
| McCarthy et al. | Acute and Chronic Vascular and Cardiac Effects of Serelaxin in the Angiotensin II/L-NAME Heart Failure Model | |
| HK40017696B (zh) | Npra激动剂、组合物及其用途 | |
| Morine et al. | Neutralizing Endoglin Activity Rescues Maladaptive Remodeling in Heart Failure | |
| WO2009080608A1 (en) | Y2 receptor agonists | |
| Chen et al. | BUNP: A Novel Designer pGC-A/cGMP Activator with Enhanced Potency and High Selectivity In Vitro | |
| La Villa et al. | Effects of atrial (ANP) and C-type (CNP) natriuretic peptide on the renal release of endothelin-1 (ET-1) in man | |
| JP2020503356A5 (https=) |